People · Operator
Named in public records as an officer, director or promoter · active 2018–2018 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Braeburn Pharmaceuticals, Inc. | — | Biotechnology | Series D+ | $110.0M | $4.5B | 2018 |
Argeris L. Karabelas, Ph.D. at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Argeris L. Karabelas, Ph.D. on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Asher M. Rubin | 1 | 2 |
| Dennis H. Langer, J. D., M.D. | 1 | 1 |
| Jeffrey L. Berkowitz | 1 | 1 |
| David J. McIntyre | 1 | 1 |
| Brian H. Markison | 1 | 1 |
| Patrick L. Kennedy | 1 | 1 |
| Michael Derkacz | 1 | 1 |
| Seth L. Harrison, M.D. | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.